Literature DB >> 6175932

Prenatal serum alpha-fetoprotein screening for neural tube defects.

J N Macri, R R Weiss.   

Abstract

Twenty-two cases of open neural tube defect were found in a population of 17,703 unselected pregnancies (1.2 per 1000) within the Long Island, New York, region. Voluntary screening of maternal serum alpha-fetoprotein levels identified 20 of the 22 cases (91%). Six hundred ninety-two participants demonstrated serial elevations in maternal serum alpha-fetoprotein. Of this group, which was designated at increased risk for open neural tube defect, 24% had underestimated gestational age, 13% had multiple gestations, and 53% were candidates for amniocentesis. In the amniocentesis group, the detection yield of neural tube defect was 20 per 365 (5.5%). Neither false-negative amniotic fluid evaluations nor termination of normal pregnancy due to false-positive amniotic fluid levels occurred. Perinatal outcome data, including pregnancy complications, date, mode of delivery, sex, birth weight, Apgar score, and congenital malformations of the neonate other than neural tube defect, are reported for the first 9300 consecutive participants of the 17,703 population study. These data identify a correlation between rate of perinatal loss and maternal serum alpha-fetoprotein levels.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6175932

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  9 in total

1.  When does mass screening for open neural tube defects in low-risk pregnancies result in cost savings?

Authors:  L L Tosi; A S Detsky; D P Roye; M L Morden
Journal:  CMAJ       Date:  1987-02-01       Impact factor: 8.262

2.  Maternal serum alpha-fetoprotein screening for neural tube defects. Report of a combined study in Germany and short overview on screening in populations with low birth prevalence of neural tube defects.

Authors:  W Fuhrmann; H K Weitzel
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

3.  Maternal serum alpha-fetoprotein screening: report of a Canadian pilot project.

Authors:  T A Doran; G H Valentine; P Y Wong; G Wielgosz; R J Benzie; H C Soltan; M R Jenner; P A Morland; R J Montgomery; L C Allen
Journal:  CMAJ       Date:  1987-08-15       Impact factor: 8.262

4.  Alpha-fetoprotein screening.

Authors:  B F Crandall
Journal:  West J Med       Date:  1984-06

5.  Epidemiology of neural tube defects in Germany.

Authors:  M Koch; W Fuhrmann
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

6.  Distress associated with prenatal screening for fetal abnormality.

Authors:  Marci Lobel; Lynette Dias; Bruce A Meyer
Journal:  J Behav Med       Date:  2005-02

7.  Maternal serum alpha-fetoprotein screening for the detection of neural tube defects.

Authors:  B F Crandall; R D Robertson; T B Lebherz; W King; P C Schroth
Journal:  West J Med       Date:  1983-04

8.  Periodic health examination, 1994 update: 3. Primary and secondary prevention of neural tube defects. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1994-07-15       Impact factor: 8.262

Review 9.  Maternal Serum Screening Markers and Adverse Outcome: A New Perspective.

Authors:  David Krantz; Terrence Hallahan; David Janik; Jonathan Carmichael
Journal:  J Clin Med       Date:  2014-07-03       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.